D
Darren W. Davis
Researcher at University of Texas MD Anderson Cancer Center
Publications - 77
Citations - 4703
Darren W. Davis is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 35, co-authored 77 publications receiving 4517 citations. Previous affiliations of Darren W. Davis include University of Texas Health Science Center at Houston & University of Chicago.
Papers
More filters
Journal Article
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Christiane J. Bruns,Matthew T. Harbison,Darren W. Davis,Charles A. Portera,Rachel Tsan,David J. McConkey,Douglas B. Evans,James L. Abbruzzese,Daniel J. Hicklin,Robert Radinsky +9 more
TL;DR: Experiments indicate that therapeutic strategies targeting EGF-R have a significant antitumor effect on human L3.6pl pancreatic carcinoma growing in nude mice which is mediated in part by inhibition of tumor-induced angiogenesis, leading to tumor cell apoptosis and regression.
Journal Article
Antiangiogenic Therapy Targeting the Tyrosine Kinase Receptor for Vascular Endothelial Growth Factor Receptor Inhibits the Growth of Colon Cancer Liver Metastasis and Induces Tumor and Endothelial Cell Apoptosis
Raymond M. Shaheen,Darren W. Davis,Wenbiao Liu,Brian K. Zebrowski,Michael R. Wilson,Corazon D. Bucana,David J. McConkey,Gerald McMahon,Lee M. Ellis +8 more
TL;DR: VEGF receptor inhibitors increased endothelial cell apoptosis, suggesting that VEGF may serve as an endothelial survival factor.
Journal ArticleDOI
Phase I study of recombinant human endostatin in patients with advanced solid tumors
Roy S. Herbst,Kenneth R. Hess,Hai T. Tran,Jennifer E. Tseng,Nizar A. Mullani,Chusilp Charnsangavej,Timothy Madden,Darren W. Davis,David J. McConkey,Michael S. O'Reilly,Lee M. Ellis,James M. Pluda,Waun Ki Hong,James L. Abbruzzese +13 more
TL;DR: In this article, the authors evaluated recombinant human endostatin (rh-Endo) in a phase I trial designed to assess safety, pharmacokinetics, and serum markers of angiogenesis in patients with solid tumors.
Journal ArticleDOI
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Ezra E.W. Cohen,Darren W. Davis,Theodore Karrison,Tanguy Y. Seiwert,Stuart J. Wong,Sreenivasa Nattam,Mark Kozloff,Joseph I. Clark,Duen-Hwa Yan,Wen Liu,Carolyn Pierce,Janet Dancey,Kerstin M. Stenson,Elizabeth A. Blair,Allison Dekker,Everett E. Vokes +15 more
TL;DR: The combination of erlotinib and bevacizumab is well tolerated in recurrent or metastatic squamous-cell carcinoma of the head and neck and a few patients seem to derive a sustained benefit and complete responses were associated with expression of putative targets in pretreatment tumour tissue.
Journal Article
Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma
Keiji Inoue,Joel W. Slaton,Paul Perrotte,Darren W. Davis,Christiane J. Bruns,Daniel J. Hicklin,David J. McConkey,Paul Sweeney,Robert Radinsky,Colin P.N. Dinney +9 more
TL;DR: Therapy with paclitaxel increases the ability of C225 to inhibit tumorigenicity and metastasis, mediated by inhibition of angiogenesis and induction of apoptosis.